News summaryJ-Star Holding via GlobeNewswireNov 16, 2026, 12:00 PM
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study of HLP003
HELPpharmaceuticals
Helus Pharma announced it will host a webcast on November 16, 2026, to reveal topline results from its Phase 3 APPROACH clinical trial evaluating HLP003 as an adjunctive treatment for major depressive disorder.